Article Versions Notes

Velasco-Ruiz A, Nuñez-Torres R, Pita G, Wildiers H, Lambrechts D, Hatse S, Delombaerde D, Van Brussel T, Alonso MR, Alvarez N, et al. POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients. Pharmaceutics. 2021; 13(11):1942. https://doi.org/10.3390/pharmaceutics13111942

Velasco-Ruiz, Alejandro, Rocio Nuñez-Torres, Guillermo Pita, Hans Wildiers, Diether Lambrechts, Sigrid Hatse, Danielle Delombaerde, Thomas Van Brussel, M. Rosario Alonso, Nuria Alvarez, and et al. 2021. "POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients" Pharmaceutics 13, no. 11: 1942. https://doi.org/10.3390/pharmaceutics13111942

Velasco-Ruiz, A., Nuñez-Torres, R., Pita, G., Wildiers, H., Lambrechts, D., Hatse, S., Delombaerde, D., Van Brussel, T., Alonso, M. R., Alvarez, N., Herraez, B., Vulsteke, C., Zamora, P., Lopez-Fernandez, T., & Gonzalez-Neira, A. (2021). POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients. Pharmaceutics, 13(11), 1942. https://doi.org/10.3390/pharmaceutics13111942